'Non-Small Cell Lung Cancer Drugs Market Worth $9.37bn in 2021' Says Visiongain Report
August 16, 2018
August 16, 2018
LONDON, England, Aug. 16 -- Visiongain, a independent media company, issued the following news release:
Visiongain's new report Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027 (https://www.visiongain.com/report/non-small-cell-lung-cancer-nsclc-drugs-market-forecast-2017-2027/): Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other indicates that the non-small cell lung cancer drugs market will see $9.37bn in spending in 2021.
Visiongain's new report Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027 (https://www.visiongain.com/report/non-small-cell-lung-cancer-nsclc-drugs-market-forecast-2017-2027/): Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other indicates that the non-small cell lung cancer drugs market will see $9.37bn in spending in 2021.